Please do not hesitate to contact us with questions or concerns about biosafety issues, or for assistance or advice in preparing approval request forms.
The Institutional Biosafety Committee (IBC) is committed to ensuring that activities of a potentially biologically hazardous nature are conducted safely and responsibly at Colorado State University (CSU). To fulfill this commitment the IBC reviews, approves, and maintains a record of all research and teaching activities by faculty, staff and students, that utilize infectious agents, human body fluids or tissues, and recombinant or synthetic nucleic acid molecules. Reviews are conducted in accordance with the NIH Guidelines for Research Involving Recombinant DNA or Synthetic Nucleic Acid Molecules(NIH Guidelines) and the CDC/HHS Biosafety in Microbiological and Biomedical Laboratories (BMBL). This review process ensures that all activities involving these materials and the facilities used to conduct such work are in compliance with current federal regulations and applicable CSU policies.
Our committee is made up of faculty, staff, and community members with diverse knowledge and expertise. We have members representing the Departments of Biochemistry and Molecular Biology; Biology; Biomedical Sciences; Microbiology, Immunology, and Pathology; and Soil and Crop Sciences. In addition, the University Bioethicist, as well as the Directors of Biosafety, Environmental Health Services and Laboratory Animal Resources all hold permanent appointments to this committee. New members are nominated by the IBC and appointed by the Vice President for Research (VPR). IBC members serve a three-year term, which may be renewed.
|Type of Review||Average Days to Approve||Number of Current Active Protocols|
|Full IBC AARF||16||727|
|Full IBC PARF||15||518|
6 month period from January 1, 2017 to July 13, 2017; Number of days are Business days only